Beckley Psytech’s Phase IIa study will explore the safety, efficacy and pharmacokinetics of a single dose of BPL-003, in combination with psychological support, in patients with Treatment Resistant Depression (TRD).
This week witnessed a wave of US states dwelling on psychedelic policies to be included in voting agendas, while cutting-edge DMT research is being subsidized for mental health studies.
The company will use proceeds of the fundraising round to complete its ongoing Phase 1B trial on low-dose psilocybin in patients suffering from a rare headache condition with no approved medications to treat it.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.